Downregulation of hypoxia-inducible factor-1α contributes to impaired megakaryopoiesis in immune thrombocytopenia
06 March 2017
Accepted after major revision: 23 June 2017
08 November 2017 (online)
Impaired megakaryocyte maturation and exaggerated platelet destruction play a pivotal role in the pathogenesis of immune thrombocytopenia (ITP). Previous studies have shown that HIF-1α promotes the homing and engraftment of haematopoietic stem cells (HSCs), thereby stimulating HSC differentiation. However, whether HIF-1α plays a role in megakaryocytic maturation and platelet destruction in ITP remains elusive. Using enzyme-linked immunosorbent assays (ELISAs), we demonstrated that there were lower HIF-1α levels in the bone marrow (BM) of ITP patients than in that of healthy donors and patients with chemotherapy-related thrombocytopenia. Subjects with lower megakaryocyte (<100/slide) and platelet (<30 × 109/L) counts exhibited significantly decreased BM HIF-1α levels, compared to those with higher megakaryocyte (≥100/slide) and platelet (≥30 × 109/L) counts. To test whether HIF-1α regulates megakaryopoiesis and platelet production, megakaryocytes derived from mouse BM cells were treated with an HIF-1α activator (IOX-2; 50 µM) or inhibitor (PX-478; 50 µM). PX-478 significantly decreased HIF-1α expression, cell size, and the populations of CD41-positive and high-ploidy cells. Importantly, to evaluate the role of HIF-1α as a potential therapeutic target in ITP, mouse BM cells were incubated with plasma from ITP patients in the presence or absence of IOX-2. IOX-2 significantly attenuated the ITP plasma-induced decrease in cell size as well as the proportions of CD41-positive and high-ploidy cells. In addition, IOX-2 increased the number of megakaryocytes from mouse BM cells treated with ITP plasma. Our findings indicate that decreased HIF-1α may contribute to impaired megakaryopoiesis in ITP, and HIF-1α may provide a potential therapy for ITP patients.
Supplementary Material to this article is available online at www.thrombosis-online.com.
- 1 Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Sem Hematol 2009; 46 (01) (Suppl. 02) S2-S14.
- 2 Stasi R, Evangelista ML, Stipa E. et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008; 99: 4-13.
- 3 Alimardani G, Guichard J, Fichelson S. et al. Pathogenic effects of anti-glycoprotein Ib antibodies on megakaryocytes and platelets. Thromb Haemost 2002; 88: 1039-1046.
- 4 Diggs LW, Hewlett JS. A study of the bone marrow from 36 patients with idiopathic hemorrhagic, thrombopenic purpura. Blood 1948; 03: 1090-1104.
- 5 Ridell B, Branehog I. The ultrastructure of the megakaryocytes in idiopathic thrombocytopenic purpura (ITP) in relation to thrombokinetics. Pathol Eur 1976; 11: 179-187.
- 6 Ballem PJ, Segal GM, Stratton JR. et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80: 33-40.
- 7 Debili N, Wendling F, Katz A. et al. The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood 1995; 86: 2516-2525.
- 8 Porcelijn L, Folman CC, Bossers B. et al. The diagnostic value of thrombopoietin level measurements in thrombocytopenia. Thromb Haemost 1998; 79: 1101-1105.
- 9 Shiozaki H, Miyawaki S, Kuwaki T. et al. Autoantibodies neutralizing thrombopoietin in a patient with amegakaryocytic thrombocytopenic purpura. Blood 2000; 95: 2187-2188.
- 10 Chen S, Su Y, Wang J. ROS-mediated platelet generation: a microenvironment-dependent manner for megakaryocyte proliferation, differentiation, and maturation. Cell Death Dis 2013; 04: e722.
- 11 Khodadi E, Asnafi AA, Shahrabi S. et al. Bone marrow niche in immune thrombocytopenia: a focus on megakaryopoiesis. Ann Hematol 2016; 95: 1765-1776.
- 12 Levesque JP, Winkler IG. Hierarchy of immature hematopoietic cells related to blood flow and niche. Curr Opin Hematol 2011; 18: 220-225.
- 13 Levesque JP, Winkler IG, Hendy J. et al. Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow. Stem Cells 2007; 25: 1954-1965.
- 14 DiPersio JF, Stadtmauer EA, Nademanee A. et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
- 15 Speth JM, Hoggatt J, Singh P. et al. Pharmacologic increase in HIF1alpha enhances hematopoietic stem and progenitor homing and engraftment. Blood 2014; 123: 203-207.
- 16 Rodeghiero F, Stasi R, Gernsheimer T. et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386-2393.
- 17 Nielsen OH, Tuckuviene R, Nielsen KR. et al. Flow cytometric measurement of platelet-associated immunoglobulin in children with newly diagnosed Immune Thrombocytopenia. Eur J Haematol 2016; 96: 397-403.
- 18 Cai FF, Xu C, Pan X. et al. Prognostic value of plasma levels of HIF-1a and PGC-1a in breast cancer. Oncotarget 2016; 07: 77793-77806.
- 19 Lee SH, van der Weyden C, Mayson E. et al. Excessive EDTA induces morphologic changes in bone marrow smears that mimic specific features of dysplasia. Int J Lab Hematol 2013; 35: 163-169.
- 20 McCrann DJ, Eliades A, Makitalo M. et al. Differential expression of NADPH oxidases in megakaryocytes and their role in polyploidy. Blood 2009; 114: 1243-1249.
- 21 Shivdasani RA, Schulze H. Culture, expansion, and differentiation of murine megakaryocytes. Curr Protoc Immunol 2005; Chapter 22: Unit 22F 6.
- 22 Semeraro F, Russo A, Gambicorti E. et al. Efficacy and vitreous levels of topical NSAIDs. Expert Opin Drug Delivery 2015; 12: 1767-1782.
- 23 Willms A, Muller C, Julich H. et al. Tumour-associated circulating microparticles: A novel liquid biopsy tool for screening and therapy monitoring of colorectal carcinoma and other epithelial neoplasia. Oncotarget 2016; 07: 30867-30875.
- 24 Williams CM, Harper MT, Poole AW. PKCalpha negatively regulates in vitro proplatelet formation and in vivo platelet production in mice. Platelets 2014; 25: 62-68.
- 25 Majka M, Baj-Krzyworzeka M, Kijowski J. et al. In vitro expansion of human megakaryocytes as a tool for studying megakaryocytic development and function. Platelets 2001; 12: 325-332.
- 26 Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment. Blood 1993; 81: 1246-1250.
- 27 Cines DB, Bussel JB, Liebman HA. et al. The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113: 6511-6521.
- 28 He R, Reid DM, Jones CE. et al. Extracellular epitopes of platelet glycoprotein Ib alpha reactive with serum antibodies from patients with chronic idiopathic thrombocytopenic purpura. Blood 1995; 86: 3789-3796.
- 29 Roark JH, Bussel JB, Cines DB. et al. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood 2002; 100: 1388-1398.
- 30 Houwerzijl EJ, Blom NR, van der Want JJ. et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004; 103: 500-506.
- 31 Pisciotta AV, Stefanini M, Dameshek W. Studies on platelets. X. Morphologic characteristics of megakaryocytes by phase contrast microscopy in normals and in patients with idiopathic thrombocytopenic purpura. Blood 1953; 08: 703-723.
- 32 Chang M, Nakagawa PA, Williams SA. et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102: 887-895.
- 33 McMillan R, Wang L, Tomer A. et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103: 1364-1369.
- 34 Imanirad P, Solaimani Kartalaei P, Crisan M. et al. HIF1alpha is a regulator of hematopoietic progenitor and stem cell development in hypoxic sites of the mouse embryo. Stem Cell Res 2014; 12: 24-35.
- 35 Huang LE, Gu J, Schau M. et al. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998; 95: 7987-7992.
- 36 Maxwell PH, Wiesener MS, Chang GW. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275.
- 37 Ohh M, Park CW, Ivan M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 02: 423-427.
- 38 Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294: 1337-1340.
- 39 Epstein AC, Gleadle JM, McNeill LA. et al. C elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107: 43-54.
- 40 Yang XD, Lamb A, Chen LF. Methylation, a new epigenetic mark for protein stability. Epigenetics 2009; 04: 429-433.
- 41 Yang Y, Bedford MT. Titivated for destruction: the methyl degron. Mol Cell 2012; 48: 487-488.
- 42 Kim Y, Nam HJ, Lee J. et al. Methylation-dependent regulation of HIF-1alpha stability restricts retinal and tumour angiogenesis. Nat Commun 2016; 07: 10347.
- 43 Zhou H, Hou Y, Liu X. et al. Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia. Thromb Haemost 2015; 113: 1021-1034.
- 44 Yoshida K, Kirito K, Yongzhen H. et al. Thrombopoietin (TPO) regulates HIF-1alpha levels through generation of mitochondrial reactive oxygen species. Intern J Hematol 2008; 88: 43-51.
- 45 de Alarcon PA, Mazur EM, Schmieder JA. In vitro megakaryocytopoiesis in children with acute idiopathic thrombocytopenic purpura. Am J Pediatr Hematol Oncol 1987; 09: 212-218.
- 46 Sugiyama H, Yagita M, Takahashi T. et al. Megakaryocytopoiesis in idiopathic thrombocytopenic purpura. Nihon Ketsueki Gakkai Zasshi 1987; 50: 119-128.
- 47 Forristal CE, Winkler IG, Nowlan B. et al. Pharmacologic stabilization of HIF-1alpha increases hematopoietic stem cell quiescence in vivo and accelerates blood recovery after severe irradiation. Blood 2013; 121: 759-769.
- 48 Besarab A, Provenzano R, Hertel J. et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transpl 2015; 30: 1665-1673.
- 49 Dore LC, Crispino JD. Transcription factor networks in erythroid cell and megakaryocyte development. Blood 2011; 118: 231-239.
- 50 Gordge MP. Megakaryocyte apoptosis: sorting out the signals. Br J Pharmacol 2005; 145: 271-273.
- 51 Ucar C, Oren H, Irken G. et al. Investigation of megakaryocyte apoptosis in children with acute and chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2003; 70: 347-352.
- 52 Scortegagna M, Ding K, Zhang Q. et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 2005; 105: 3133-3140.